Mineralys Therapeutics (MLYS) Cash & Equivalents (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Cash & Equivalents data on file, last reported at $111.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 32.35% year-over-year to $111.6 million; the trailing twelve-month figure through Mar 2026 stood at $111.6 million (down 32.35% YoY), and the FY2025 full-year result was $172.9 million, up 51.56% from the prior year.
• Cash & Equivalents eased to $111.6 million in Q1 2026, from $172.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $217.6 million in Q3 2025 to a low of $49.3 million in Q4 2023.
• A 5-year average of $113.4 million and a median of $99.0 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 43.78% in 2023 and jumped 131.4% in 2024, its largest moves.
• Tracing MLYS's Cash & Equivalents over 5 years: stood at $87.7 million in 2022, then sank by 43.78% to $49.3 million in 2023, then jumped by 131.4% to $114.1 million in 2024, then jumped by 51.56% to $172.9 million in 2025, then sank by 35.45% to $111.6 million in 2026.
• Business Quant data shows MLYS's Cash & Equivalents at $111.6 million in Q1 2026, $172.9 million in Q4 2025, and $217.6 million in Q3 2025.